
|Articles|January 15, 2005
FDA approval of AMD treatment considered 'a milestone'
On Dec. 17, Eyetech Pharmaceuticals (EYET) announced FDA approval of pegaptanib sodium injection (Macugen) for the treatment of neovascular ("wet") age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Study identifies 6 key genes linking air pollution to dry eye disease
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Avisi Technologies releases positive 12-month data from VITA Trial
5


















































.png)


